Meril Life Sciences and Japan Lifeline have solidified an agreement enabling Japan Lifeline to promote Meril’s innovative transcatheter heart valve, Myval Octacor, in Japan, pending regulatory approvals. This pivotal alliance marks a significant step in advancing cardiac care within the region.

The Myval Octacor stands as a balloon-expandable transcatheter heart valve implant, meticulously crafted for Transcatheter Aortic Valve Replacement / Implantation (TAVR / TAVI) procedures.

Distinguished by its versatile range of sizes catering to a diverse patient population, this groundbreaking implant boasts an octagonal cell structure, promising heightened precision in placement. Notably, Meril has successfully implanted over 25,000 heart valves across 75 countries, cementing its global impact in cardiac interventions.

Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, expressed confidence in this collaborative venture with Japan Lifeline, emphasizing the anticipated enhancement of patient outcomes resulting from their partnership.

Keisuke Suzuki, President and CEO of Japan Lifeline, conveyed enthusiasm regarding the agreement, citing their three-decade-long involvement in heart valve disease treatment. He expressed heartfelt sentiment as Japan Lifeline prepares to reintroduce a next-generation TAVR / TAVI technology boasting proven clinical efficacy on a global scale.

This strategic collaboration between Meril Life Sciences and Japan Lifeline signifies a promising milestone in advancing cardiac healthcare solutions, poised to impact patient care and treatment efficacy in Japan's medical landscape.